Chardan Capital assumed coverage on shares of Kamada (NASDAQ:KMDA) in a research note released on Friday. The firm issued a buy rating and a $7.00 target price on the biotechnology company’s stock.
A number of other analysts have also weighed in on KMDA. ValuEngine lowered Kamada from a hold rating to a sell rating in a report on Friday. Zacks Investment Research lowered Kamada from a hold rating to a strong sell rating in a report on Thursday, November 16th. Finally, Jefferies Group reiterated a buy rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $8.00.
Kamada (NASDAQ KMDA) traded down $0.20 during trading on Friday, reaching $5.20. The company’s stock had a trading volume of 13,349 shares, compared to its average volume of 32,419. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.73 and a current ratio of 3.71. The stock has a market capitalization of $217.77, a price-to-earnings ratio of -129.97 and a beta of 1.14. Kamada has a one year low of $3.75 and a one year high of $8.61.
Kamada (NASDAQ:KMDA) last posted its earnings results on Monday, November 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. Kamada had a negative return on equity of 1.64% and a negative net margin of 1.27%. research analysts anticipate that Kamada will post 0.08 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Paulson & CO. Inc. lifted its holdings in shares of Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the last quarter. Navellier & Associates Inc acquired a new position in shares of Kamada in the 2nd quarter valued at $303,000. Vanguard Group Inc. increased its position in shares of Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after acquiring an additional 28,382 shares during the period. Analyst IMS Investment Management Services Ltd. increased its position in shares of Kamada by 125.5% in the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Kamada in the 3rd quarter valued at $112,000. Hedge funds and other institutional investors own 6.26% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/03/kamada-kmda-now-covered-by-analysts-at-chardan-capital.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.